BiTE Therapy Toxicities: Cytokine Release Syndrome (CRS)-BiTE Therapy Toxicities Infographic

Pdf Summary

The document is a quick clinical guide for nurses and care teams on <strong>cytokine release syndrome (CRS)</strong> associated with <strong>bispecific T-cell engager (BiTE) therapy</strong> for <strong>small cell lung cancer</strong>.

<h3>Key points:</h3>
- <strong>What causes CRS:</strong> BiTEs redirect T-cells to attack tumor cells, which can trigger immune overactivation and rapid cytokine release.
- <strong>Common symptoms:</strong> flu-like symptoms, malaise, fever, rigors, tachycardia, hypoxia, hypotension, and possible organ dysfunction.
- <strong>When it occurs most often:</strong> CRS is highest early in treatment, especially on <strong>Cycle 1 Day 1</strong>. Rates are mainly <strong>Grade 1–2</strong>, then decrease by <strong>Day 8</strong>, <strong>Day 15</strong>, and drop sharply in later cycles.

<h3>Nursing/clinical workflow:</h3>
1. <strong>Pre-infusion</strong>
   - Review autoimmune history
   - Perform baseline neuro assessment
   - Educate patient and caregiver on CRS and step-up dosing

2. <strong>Infusion day</strong>
   - Closely monitor vital signs, especially during <strong>hours 0–8</strong>
   - Watch for early CRS symptoms

3. <strong>Documentation</strong>
   - Report fever
   - Give clear instructions to the patient and caregiver

4. <strong>Post-infusion</strong>
   - Reinforce hydration
   - Review symptom reporting and when to seek help

<h3>CRS management:</h3>
- <strong>Fluids</strong>
- <strong>Oxygen</strong>
- <strong>Antipyretics</strong>
- <strong>Tocilizumab</strong> or other <strong>IL-6 blockade</strong> options
- <strong>Steroids</strong> such as dexamethasone
- <strong>Hold BiTE therapy</strong> until symptoms resolve
- <strong>ICU care</strong> for unstable hemodynamics or vasopressor need
- For <strong>tarlatamab</strong>, discontinue if <strong>recurrent Grade 3 CRS</strong>

Overall, the guide emphasizes early recognition, close monitoring, and prompt intervention to reduce CRS severity and improve patient safety.

Asset Subtitle

Frank Weinberg, MD, PhD

Asset Caption

Frank Weinberg, MD, PhD

Keywords

cytokine release syndrome

CRS

bispecific T-cell engager

BiTE therapy

small cell lung cancer

nursing workflow

tocilizumab

IL-6 blockade

step-up dosing

patient monitoring